NetScientific plc (“NetScientific” or the “Company”) General Counsel Strategic Hire and Grant of Options NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation group, is delighted to announce the appointment of its first General Counsel, Ed Hooper, with immediate effect. Ed also joins as Group Company Secretary and as Executive Director to the Company's corporate finance specialist subsidiary,…
NetScientific plc (“NetScientific”, the “Group” or the “Company”) ProAxsis Update ProAxsis announces “impressive” results in performance evaluation of the in-licensed AstraZeneca COVID-19 antibody test Successful completion of evaluation of the AstraZeneca COVID-19 antibody test The assay showed exceptional levels of sensitivity and specificity of 100% and 99.3% respectively Successful development strengthens ProAxsis’s expanding product range and international customer offering Additive to NetScientific’s…
NetScientific plc ("NetScientific", “NSCI”, the Group” or the "Company") Preliminary Results for the year ended 31 December 2021 Good results demonstrate excellent progress in growth strategy to realise shareholder returns NetScientific plc (AIM: NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces its preliminary results for the year ended 31 December 2021. This was an excellent year…
11th May 2022 NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), today provided a business update and first-quarter financial results for the year ended December 31, 2022.…
NetScientific plc ("NetScientific", the "Group" or the "Company") Notice of Results Investor Presentation NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, will announce results for the year ended 31 December 2021 on Thursday 12 May. Analyst Briefing: 09.30, Thursday 12 May Management will be hosting a remote presentation via web conference on the day of the…
NetScientific plc (“NetScientific”, the “Group” or the “Company”) Acquisition of 30% of Vortex Biotech Holdings NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group announces the conditional acquisition of a 30 per cent. stake in Vortex Biotech Holdings Ltd (“VBHL”) (the “Acquisition”). The Acquisition is conditional upon the receipt by Deeptech Disruptive Growth Investments Ltd (“Deeptech”) of…
NetScientific plc ("NetScientific" or the "Group") PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results London, UK – 31 March 2022 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), today provided a business update and announced its financial results for the year ended December…
NetScientific Q1 2022 Newsletter (Click to view full Newsletter) Dear NetScientific PLC Shareholders and Stakeholders, In advance of the annual report which will be published at the beginning of April, we would like to provide you with a brief update. Management remains confident in the Company’s long-term prospects despite the ongoing broader market challenges. The last few months have seen significant turmoil in…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With Merck’s anti PD-therapy KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Clinical Trial with Mayo Clinic PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer The study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer London, UK – 15 February 2022 - NetScientific plc (AIM: NSCI), the international life sciences…
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.